Details of the Drug

General Information of Drug (ID: DMTIGA0)

Drug Name
Acrivastine
Synonyms
Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Common cold CA00 Approved [2]
Seasonal allergic rhinitis CA08.01 Approved [2]
Vasomotor/allergic rhinitis CA08 Approved [2]
Therapeutic Class
Antiinflammatory Agents
ATC Code
R06AX18: Acrivastine
R06AX: Other antihistamines for systemic use
R06A: ANTIHISTAMINES FOR SYSTEMIC USE
R06: ANTIHISTAMINES FOR SYSTEMIC USE
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 348.4
Logarithm of the Partition Coefficient (xlogp) 1.6
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance
The clearance of drug is 2.9 +/- 0.7 mL/min/kg []
Elimination
67% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.9 +/- 0.3 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.31116 micromolar/kg/day [5]
Vd
The volume of distribution (Vd) of drug is 0.46 +/- 0.05 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 0.7 mg/mL [3]
Chemical Identifiers
Formula
C22H24N2O2
IUPAC Name
(E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
Canonical SMILES
CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC(=N3)/C=C/C(=O)O
InChI
InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
InChIKey
PWACSDKDOHSSQD-IUTFFREVSA-N
Cross-matching ID
PubChem CID
5284514
ChEBI ID
CHEMBL83168
CAS Number
87848-99-5
UNII
A20F9XAI7W
DrugBank ID
DB09488
TTD ID
D0O4EU
VARIDT ID
DR01418
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
P-glycoprotein 1 (ABCB1) DTP P-GP 6.54E-01 1.95E-01 4.04E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Acrivastine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Acrivastine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [9]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Acrivastine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [10]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Acrivastine and Esketamine. Depression [6A70-6A7Z] [11]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Acrivastine and Belladonna. Infectious gastroenteritis/colitis [1A40] [12]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Acrivastine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [13]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Acrivastine and Lasmiditan. Migraine [8A80] [14]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Acrivastine and Methylscopolamine. Peptic ulcer [DA61] [12]
⏷ Show the Full List of 7 DDI Information of This Drug

References

1 Comparative tolerability of second generation antihistamines. Drug Saf. 1999 May;20(5):385-401.
2 Acrivastine FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52.
7 Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
8 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
9 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
10 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
11 Cerner Multum, Inc. "Australian Product Information.".
12 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
13 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
14 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.